DiaMedica Therapeutics Inc.·Healthcare

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), today provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference call on Tuesday, March 31, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discus.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.

Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial resu.

DiaMedica Therapeutics (NASDAQ: DMAC - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.17) per share for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.